|
Filovirus Animal Non-Clinical Group (FANG) Workshop
|
Meeting/ Workshop
|
CDC, FDA, OS
|
NIAID
|
The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The primary focus of the Workshop will be on Marburg virus, although other filoviruses will also be addressed.
|
|
FNIH Biomarkers Consortium
|
Research Initiative
|
CMS, FDA
|
NIMH, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIDDK, NIEHS, NINDS
|
The Biomarkers Consortium is a major public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) with broad participation from stakeholders across the health field, including government, industry, academia, patient advocacy and other not-for-profit organizations. In addition to the FNIH, founding members include the National Institutes of Health, Food and Drug Administration, and the Pharmaceutical Research and Manufacturers of America. The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers to enable improvements in drug development, clinical care, and regulatory decision-making.
|
|
Food and Drug Administration (FDA) Cancer Imaging Program (CIP) Bi-annual Meeting
|
Meeting/ Workshop
|
FDA
|
NCI
|
This collaboration is a bi-annual meeting to enhance communication between the Cancer Imaging Program (CIP) and the Division of Medical Imaging Products of the Center for Drug Evaluation and Research (CDER) in the Food and Drug Administration (FDA). This allows for a two-way exchange of information and discussion of issues that are important for each side. Topics that have been discussed include CIP''s standardization efforts of medical imaging scanners in the National Cancer Institute''s (NCI) Cancer Centers, presentation and discussion of specific new molecular imaging modalities, and discussion of recent FDA decisions regarding newmedical imaging innovations.
|
|
Forum on Regenerative Medicine
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIDCR, NHLBI, NIAMS, NIBIB, NIDDK, NINDS
|
Six National Institutes of Health (NIH) institutes and the Food and Drug Administration (FDA) are participating in a multi-year National Academy of Medicine (NAM)-led activity entitled "Forum on Regenerative Medicine". The objective of the Forum is to engage key stakeholders of regenerative medicine in a dialogue about opportunities and challenges facing translation of regenerative medicine science and technologies to the clinic. The setting of the NAM provides a neutral convening mechanism for interactions between academia, industry, government, regulators, patients’ organizations, foundations, and others. In addition to science, ethical, legal, and societal issues related to regenerative
medicine are discussed. In October 2016 the Forum supported a highly successful interdisciplinary workshop that examined the current state of science in regenerative medicine. Further activities are currently being planned.
|
|
Foundation for the National Institutes of Health (FNIH) PACT (Partnership for Accelerating Cancer Therapies)
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI
|
The Partnership for Accelerating Cancer Therapies (PACT) is a five-year public-private research collaboration totaling $215 million launched by the National Institutes of Health, the FNIH (Foundation for the NIH) and 11 leading pharmaceutical companies as part of the Cancer Moonshot. PACT will initially focus on efforts to identify, develop and validate robust biomarkers — standardized biological markers of disease and treatment response — to advance new immunotherapy treatments that harness the immune system to attack cancer. The partnership will be managed by the FNIH, with the Food and Drug Administration serving in an advisory role.
|
|
Full-text health-related documents at NLM (includes HSTAT)
|
Resource Development
|
AHRQ, ATSDR, CDC, CMS, FDA, OSG, SAMHSA
|
NLM
|
The National Library of Medicine of the National Institutes of Health provides a free, web-based resource of full-text documents that provide information on health-care decision making.
|
|
Funding Opportunity Announcement Module (FOAM)
|
Resource Development
|
ACF
|
OD/OER, NHLBI
|
The Funding Opportunity Announcement Module (FOAM) allows NIH Institutes and Centers and HHS Operating Divisions to develop content for and perform the needed approvals to publish funding opportunity announcements. The system has a flexible configuration to meet all of the needs for HHS Operating Divisions. Furthermore, FOAM achieves economies of scale by preventing the need for individual agencies to develop duplicate systems at a cost much greater than that of developing a unified system.
|
|
Gabriella Miller Kids First Common Fund Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NICHD, NCI, NEI, NHGRI, NHLBI, NIAAA, NIAMS, NIDA, NIDCR, NIDDK, NIEHS, NINDS, OD/DPCPSI/ORIP
|
The National Institutes of Health (NIH) Gabriella Miller Kids First Common Fund Working Group supports the goals and initiatives of the NIH Gabriella Miller Kids First Common Fund Pediatric Research Program (Kids First). Kids First is developing a data resource for the pediatric research community of well-curated clinical and genetic sequence data that will allow scientists to identify genetic pathways that underlie specific pediatric conditions but that may also be shared between apparently disparate conditions. A representative from the Centers for Disease Control and Prevention (CDC) participates in the Kids First Working Group.
|
|
Genetic Studies in the National Birth Defects Prevention Study
|
Research Initiative
|
CDC
|
NHGRI
|
This study is a collaboration between The Centers for Disease Control and Prevention (CDC) and the National Human Genome Research Institute (NHGRI) to carry out DNA sequencing and genotyping on samples collected as part of the National Birth Defects Prevention Study.
|
|
GeT-RM Browser
|
Resource Development
|
CDC
|
NLM
|
The GeT-RM Coordination Program is a Centers for Disease Control and Prevention (CDC) project for establishing a community process to create reference materials, quality control measures, and proficiency testing for genetic testing. The GeT-RM Browser is provided by National Center for Biotechnology Information (NCBI) to facilitate access to the data generated by this project, which is intended to aid evaluation of the analytical validity of next-generation sequencing assays.
|